Trials / Completed
CompletedNCT01002820
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
A Treatment Protocol for Ganaxolone as add-on Therapy in Adult Patients With Uncontrolled Partial-onset Seizures Deriving Benefit From Protocol 1042-0601
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Marinus Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ganaxolone | liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-10-01
- Completion
- 2013-08-01
- First posted
- 2009-10-27
- Last updated
- 2022-09-07
- Results posted
- 2022-09-07
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01002820. Inclusion in this directory is not an endorsement.